Bolt Biotherapeutics discloses new STING agonist immunoconjugates

AI Briefing

• – Bolt Biotherapeutics develops cancer treatment candidates
• – New immunoconjugates link antibodies to STING agonists
• – Designed for potential use in treating various types of cancer